Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 11,584 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: CHRONIC DISEASE Clear all

Conditions: Cystic Fibrosis
Interventions: Elexacaftor-tezacaftor-ivacaftor exposure; Drug
Lead sponsor: Jennifer Taylor-Cousar; Other
Eligibility: 18 Years to 89 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Metabolic Bone Disease
Interventions: Lanthanum Carbonate (Fosrenol), placebo; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Knowledge, Attitudes, Practice
Interventions: Sleep Care Positioning Training Program GRP1, Sleep Care Positioning Training Program GRP2; Other
Lead sponsor: St. Catherine University; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Acute Liver Failure, Acute Liver Injury, Drug Induced, Acute on Chronic Liver Failure (ACLF), Acute Alcoholic Hepatitis
Interventions: miroliverELAP treatment; Combination Product
Lead sponsor: Miromatrix Medical Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 8
States / cities: Chicago, Illinois • Ann Arbor, Michigan • Minneapolis, Minnesota + 5 more

Conditions: Meniere Disease, Ménière
Interventions: Ebselen, Placebo; Drug
Lead sponsor: Sound Pharmaceuticals, Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 12
States / cities: Little Rock, Arkansas • Los Angeles, California • Roseville, California + 8 more

Conditions: Chronic Kidney Diseases, Cardiovascular Diseases
Interventions: Not listed
Lead sponsor: University of Miami; Other
Eligibility: Up to 10 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2029
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Peripheral Arterial Disease, Critical Limb Ischemia
Interventions: Serranator, POBA; Device
Lead sponsor: Cagent Vascular LLC; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Obesity and Obesity-related Medical Conditions, Diabetes, Atherosclerotic Disease, Heart Failure, MASH, Sarcopenia, Osteoporosis, Hyperparathyroidism, Hypoparathyroidism, Ischemic Heart Disease, Cystic Fibrosis (CF), Chronic Kidney Disease(CKD), Osteopenia, Cachexia
Interventions: Endothelial cell collection; Other
Lead sponsor: Bettina Mittendorfer; Other
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Critical Limb Ischemia
Interventions: Liposuction, Stem Cell Injection; Procedure · Other
Lead sponsor: Ageless Regenerative Institute; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hidradenitis Suppurativa
Interventions: Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 36
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • North Little Rock, Arkansas + 32 more

Conditions: Acute Undifferentiated Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Blastic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions: GTI-2040, pharmacological study, laboratory biomarker analysis; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Duarte, California

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
Interventions: JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax; Biological
Lead sponsor: Juno Therapeutics, a Subsidiary of Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 83
States / cities: Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 41 more

Conditions: Cerebral Palsy, Typically Developing Children
Interventions: MRI, HD-EEG Recording, rTMS; Device
Lead sponsor: Cook Children's Health Care System; Other
Eligibility: 6 Years to 20 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Neurological Disorder, Cerebral Palsy
Interventions: Gait Training, Transcutaneous Spinal Stimulation; Other · Device
Lead sponsor: University of Washington; Other
Eligibility: 4 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Chronic Graft Versus Host Disease
Interventions: bortezomib, Prednisone; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV-1 Infection
Interventions: E/C/F/TAF, B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 19
States / cities: Los Angeles, California • Sacramento, California • Ft. Pierce, Florida + 16 more

Conditions: Leukemia, Myelodysplastic Syndromes
Interventions: natural killer cell therapy, cyclophosphamide, fludarabine; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 120 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: End Stage Renal Disease on Hemodialysis (Diagnosis)
Interventions: HEPLISAV-B®; Drug
Lead sponsor: Dynavax Technologies Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 20
States / cities: Bloomfield, Connecticut • Middlebury, Connecticut • Hollywood, Florida + 17 more

Conditions: Covid19
Interventions: Not listed
Lead sponsor: Tulane University; Other
Eligibility: 6 Months to 120 Years
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: New Orleans, Louisiana

Conditions: Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: pegylated liposomal doxorubicin hydrochloride, picoplatin; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: New York, New York

Conditions: Post-Stroke Chronic Aphasia
Interventions: Semantic Feature Ecological Momentary Intervention; Behavioral
Lead sponsor: Northeastern University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Dysequilibrium Syndrome, ESRD, Hyperkalemia, Metabolic Acidosis
Interventions: Urea in the dialysate; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pediatrics, Muscle Spasticity, Cerebral Palsy
Interventions: botulinum toxin Type A, Normal Saline (Placebo); Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 2 Years to 16 Years
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 24
States / cities: Pasadena, California • Pomona, California • Aurora, Colorado + 19 more

Conditions: B Acute Lymphoblastic Leukemia Associated With Down Syndrome, Down Syndrome, Myeloid Leukemia Associated With Down Syndrome
Interventions: Biospecimen Collection, Clinical Evaluation, Neurocognitive Assessment, Questionnaire Administration, Survey Administration; Procedure · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 6 Years to 39 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 72
States / cities: Birmingham, Alabama • Phoenix, Arizona • Madera, California + 60 more

Search by objective public record fields.

Impact of Triple Combination CFTR Therapy on Sinus Disease.

The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 ( FGF23) in Chronic Kidney Disease

Nighttime Postural Care: Caregiver Training Program and Outcome Measure Feasibility

miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial

SPI-1005 for the Treatment of Meniere's Disease

BLOOM: Biological Legacy of Origin in Mother-Infant Dyads

Serranator Recoil Study

Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)

Autologous Adipose-Derived Stromal Cell Delivered Via Intramuscular Injections for the Treatment of Critical Limb Ischemia

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Repetitive Transcranial Magnetic Stimulation on Motor Function and Meta-Plasticity in Cerebral Palsy: TMS-EEG Study

Transcutaneous Stimulation for Neurological Populations

Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis

Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant

HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis

Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasure Development

ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma

Ecological Momentary Intervention for Post-Stroke Anomia

Adding Urea to the Final Dialysis Fluid

BOTOX® Treatment in Pediatric Lower Limb Spasticity

A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia